Targeted disruption of TGF-β-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury

Circulation Research

Volumn 96, Issue 8, 2005, Pages 904-912

  Kobayashi, Kazuki ^a   Yokote, Koutaro ^a,b   Fujimoto, Masaki ^a   Yamashita, Kimihiro ^b   Sakamoto, Akemi ^a   Kitahara, Masaki ^c   Kawamura, Harukiyo ^a   Maezawa, Yoshiro ^a   Asaumi, Sunao ^a   Tokuhisa, Takeshi ^a   Mori, Seijiro ^a   Saito, Yasushi ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Atherosclerosis; Neointimal hyperplasia; Smad3; Smooth muscle cells; Transforming growth factor

Indexed keywords

ALPHA2 COLLAGEN TYPE 1; COLLAGEN TYPE 1; MATRIX METALLOPROTEINASE; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CHEMOTAXIS; FEMORAL ARTERY; GROWTH INHIBITION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALS; ARTERIOSCLEROSIS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; DNA-BINDING PROTEINS; HYPERPLASIA; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MICE; MUSCLE, SMOOTH, VASCULAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUNICA INTIMA;

EID: 20944432235     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000163980.55495.44     Document Type: Article

References (51)

1. Roberts AB, Sporn MB. The transforming growth factor-betas. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors. Heidelberg, Germany: Springer-Verlag; 1990;95:419-472.
2. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med. 2000;342:1350-1358.
3. Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992;90:1582-1592.
4. Laiho M, Rönnstrand L, Heino J, Decaprio JA, Ludlow JW, Livingston DM, Massagué J. Control of junB and extracellular matrix protein expression by transforming growth factor-beta 1 is independent of simian virus 40 T antigen-sensitive growth-sensitive growth-inhibitory events. Mol Cell Biol. 1991;11:972-978.
5. Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337-4345.
6. Westerhausen DR Jr, Hopkins WE, Billadello JJ. Multiple transforming growth factor- β-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem. 1991;266:1092-1100.
7. Eickelberg O, Köhler E, Reichenberger F, Bertschin S, Woodtli T, Erne P, Perruchoud AP, Roth M. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-β1 and TGF-β3. Am J Physiol. 1999;276:L814-L824.
8. Uría JA, Jiménez MG, Balbín M, Freije JM, López-Otín C. Differential effects of transforming growth factor-β on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem. 1998;273:9769-9777.
9. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759-10763.
10. Schulick AH, Taylor AJ, Zuo W, Qiu C-B, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA. Overexpression of transforming growth factor β1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A. 1998;95:6983-6988.
11. Wolf YG, Rasmussen LM, Rouslahti E. Antibodies against transforming growth factor-b1 suppresses intimal hyperplasia in a rat model. J Clin Invest. 1994;93:1172-1178.
12. Kingston PA, Sinha S, David A, Castro MG, Lowenstein PR, Heagerty AM. Adenovirus-mediated gene transfer of a secreted transforming growth factor-β type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition. Circulation. 2001;104:2595-2601.
13. Yamamoto K, Morishita R, Tomita N, Shimozato T, Nakagami H, Kikuchi A, Aoki M, Higaki J, Kaneda Y, Ogihara T. Ribozyme oligonucleotides against transforming growth factor-β inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation. 2000;102:1308-1314.
14. Morisaki N, Kawano M, Koyama N, Koshikawa T, Umemiya K, Saito Y, Yoshida S. Effects of transforming growth factor-beta 1 on growth of aortic smooth muscle cells. Influences of interaction with growth factors, cell state, cell phenotype, and cell cycle. Atherosclerosis. 1991;88:227-234.
15. Goodman LV, Majack RA. Vascular smooth muscle cells express distinct transforming growth factor-β receptor phenotypes as a function of cell density in culture. J Biol Chem. 1989;264:5241-5244.
16. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, Daemen MJ. Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol. 2002;22:975-982.
17. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, Merval R, Fradelizi D, Tedgui A. Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934.
18. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 2003;112:1342-1350.
19. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, Weksler BB, Sanbora TA, Bergman G, Bush HL Jr. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest. 1997;100:2182-2188.
20. McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, Deutsch E, Tarazona N, Shaknovitch A, Newman G, Patterson C, Bush HL Jr. The expression of TGF-β receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol. 1999;31:1627-1642.
21. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.
22. Heldin C-H, Miyazono K, ten Dijke P. TGF- β signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997;390:465-471.
23. Massagué J, Chen Y-G. Controlling TGF-β signaling. Genes Dev 2000;14:627-644.
24. Sirard C, de la Pompa JL, Elia A, Itie A, Mirtsos C, Cheung A, Hahn S, Wakeham A, Schwartz L, Kern SE, Rossant J, Mak TW. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev. 1998;12:107-119.
25. Yang X, Li C, Xu X, Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci U S A. 1998;95:3667-3672.
26. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell. 1998;92:797-808.
27. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999;18:1280-1291.
28. Kikuchi S, Umemura K, Kondo K, Saniabadi AR, Nakashima M. Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimal thickening. Arterioscler Thromb Vasc Biol. 1998;18:1069-1078.
29. Yamashita K, Sakamoto A, Ohkubo Y, Arima M, Hatano M, Kuroda Y, Tokuhisa T. C-fos overexpression in splenic B cells augments development of marginal zone B cells. Mol Immunol. 2005;42:617-625.
30. Ohmi K, Masuda T, Yamaguchi H, Sakurai T, Kudo Y, Katsuki M, Nonomura Y. A novel aortic smooth muscle cell line obtained from p53 knock out mice expresses several differentiation characteristics. Biochem Biophys Res Commun. 1997;238:154-158.
31. Hasegawa K, Arakawa E, Oda S, Yanai N, Obinata M, Matsuda Y. Novel smooth muscle cell lines from transgenic mice harboring temperature-sensitive SV40 large T-antigen gene: temperature-dependent expression of smooth muscle myosin heavy chain-1 and calponin genes. J Mol Cell Cardiol. 1997;29:2177-2186.
32. Yokote K, Mori S, Hansen K, McGlade J, Pawson T, Heldin CH, Claesson-Welsh L. Direct interaction between She and the platelet-derived growth factor β-receptor. J Biol Chem. 1994;269:15337-15343.
33. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF. Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction. Mol Cell Biol. 1999;19:2495-2504.
34. Yokote K, Mori S, Siegbahn A, Ronnstrand L, Wernstedt C, Heldin CH, Claesson-Welsh L. Structural determinants in the platelet-derived growth factor α-receptor implicated in modulation of chemotaxis. J Biol Chem. 1996;271:5101-5111.
35. Fischer-Dzoga K, Dimitrievich GS, Griem ML. Radiosensitivity of vascular tissue. II: differential radiosensitivity of aortic cells in vitro. Radiat Res. 1984;99:536-546.
36. Waksman R, Robinson KA, Crocker IR, Gravanis MB, Cipolla GD, King SB 3rd. Endovascular low-dose irradiation inhibits neointima formation after coronary artery balloon injury in swine: a possible role for radiation therapy in restenosis prevention. Circulation. 1995;91:1533-1539.
37. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol. 1999;1:260-266.
38. Lijnen HR, Soloway P, Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ Res. 1999;85:1186-1191.
39. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852-859.
40. Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler Stevenson WG, Seiki M. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett. 1996;385:238-240.
41. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.
42. Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med. 1995;1:1067-1073.
43. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995;311:977-980.
44. Kanzaki T, Tamura K, Takahashi K, Saito Y, Akikusa B, Oohashi H, Kasayuki N, Ueda M, Morisaki N. In vivo effect of TGF-β1: enhanced intimal thickening by administration of TGF-β1 in rabbit arteries injured with a balloon catheter. Arterioscler Thromb Vasc Biol. 1995;15:1951-1957.
45. Yuan W, Varga J. Transforming growth factor- β repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem. 2001;276:38502-38510.
46. Xu G, Chakraborty C, Lala PK. Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotesse-1 upregulation in human choriocarcinoma cells. Biochem Biophys Res Commun. 2003;300:383-390.
47. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004;85:47-64.
48. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
49. Chung IM, Ueno H, Pak YK, Kim JW, Choi DH, Shin GJ, Yang WI, Jang Y. Catheter-based adenovirus-mediated local intravascular gene delivery of a soluble TGF-β type II receptor using an infiltrator in porcine coronary arteries: efficacy and complications. Exp Mol Me. 2002;34:299-307.
50. Inoue S, Orimo A, Hosoi T, Ikegami A, Kozaki K, Ouchi Y, Nomura S, Muramatsu M, Orimo H. Demonstration of activin-A in arteriosclerotic lesions. Biochem Biophys Res Commun. 1994;205:441-448.
51. Engelse MA, Neele JM, van Achterberg TA, van Aken BE, van Schaik RH, Pannekoek H, de Vries CJ. Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res. 1999;85:931-939.